NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

HappyLibrarian,

All that discussion has happened too and it is clear demand is expected to ramp much quicker than anything in recent history in the oncology space due to the platform technology it represents which means the kind of manufacturing needed to meet that demand must be readily scalable now. Safety is not an issue so once approved for GBM and rGBM any cancer expressing mesenchymal biomarkers will likely be potential candidates for off label use then approved indications not long after. Direct trials will get almost instant full enrollment and obvious advantage will bee seen in just a few months or less from start of treatment and buildout of capacity takes time even with lots of money involved. If you or others that have been here for any significant amount of time can’t see that this is what is coming by now and that we have had to wait this process out for regulators to get ready too then you probably won’t until after the fact which is a common trait among all of us at one time or another.. Best wishes.